The choroidal circulation is integral to ocular health, supplying oxygen and nutrients to the outer retina and retinal pigment epithelium. Recent advances in imaging and clinical research have established alterations in choroidal blood flow and thickness as potential predictors and biomarkers for various ocular diseases. This review synthesizes current evidence on the clinical significance, pathophysiological mechanisms, diagnostic approaches, and therapeutic implications of choroidal circulation changes, with an emphasis on their predictive utility across a spectrum of eye disorders. Emphasis is placed on integrating the latest findings from PubMed-indexed literature to inform practice and highlight avenues for future research.
The choroid, a vascular layer of the eye located between the retina and sclera, plays a pivotal role in the sustenance of retinal function. Its unique vascular architecture ensures the metabolic demands of the outer retina are met, while also facilitating thermoregulation and waste removal. Advances in ocular imaging, such as enhanced depth imaging optical coherence tomography (EDI-OCT) and optical coherence tomography angiography (OCTA), have enabled clinicians to visualize and quantify choroidal structure and perfusion with unprecedented clarity. Variations in choroidal thickness, perfusion indices, and vascular reactivity are now recognized as significant predictors of several ocular pathologies, including age-related macular degeneration (AMD), central serous chorioretinopathy (CSC), diabetic retinopathy (DR), and glaucoma. Understanding these changes is crucial for early detection, risk stratification, and personalized management of ocular diseases.
Ocular diseases linked to abnormal choroidal circulation represent a substantial global health burden. AMD is the leading cause of irreversible vision loss in individuals over 60 years, with a prevalence exceeding 8% in this demographic. CSC, characterized by localized serous detachment of the neurosensory retina, predominantly affects middle-aged men and is associated with significant morbidity. Diabetic retinopathy, a microvascular complication of diabetes, affects approximately one-third of diabetic patients worldwide, with choroidal changes increasingly recognized as contributing to its pathogenesis. Glaucoma, a leading cause of blindness, is also associated with compromised choroidal perfusion. Collectively, these conditions underscore the epidemiological importance of monitoring choroidal circulation in at-risk populations.
The choroid is richly supplied by the posterior ciliary arteries and is under autonomic control, allowing dynamic regulation of blood flow. Pathological alterations in the choroidal vasculature can arise from systemic factors (such as hypertension, diabetes, and dyslipidemia), local inflammatory processes, or genetic predispositions. In AMD, choroidal thinning and hypoperfusion precede photoreceptor degeneration, implicating ischemia in disease progression. In CSC, choroidal hyperpermeability and vascular congestion result in increased hydrostatic pressure and leakage beneath the retina. Diabetic choroidopathy manifests as capillary dropout, ischemia, and increased vascular permeability, exacerbating retinal injury. In glaucoma, reduced choroidal blood flow may contribute to optic nerve head ischemia and progressive visual field loss. These mechanistic insights highlight the interplay between choroidal circulation and ocular disease pathogenesis.
Choroidal circulation is influenced by a constellation of modifiable and non-modifiable risk factors. Age-related vascular sclerosis, systemic hypertension, and diabetes mellitus are established systemic risk factors. Genetic predispositions, such as polymorphisms in complement factor H and ARMS2 genes, modulate susceptibility to choroidal vascular changes in AMD. Corticosteroid use, psychological stress, and sleep disturbances are notable precipitants in CSC. Smoking and dyslipidemia further compromise choroidal perfusion and integrity. A comprehensive assessment of these risk factors is essential for identifying individuals at heightened risk for choroidal circulation abnormalities and related ocular diseases.
Alterations in choroidal circulation manifest clinically in diverse ways. In AMD, early signs include drusen formation and pigmentary changes, with late-stage geographic atrophy or neovascularization corresponding to profound choroidal thinning. CSC presents with acute or chronic central vision distortion, often linked to increased choroidal thickness. Diabetic patients may exhibit subtle visual impairment even before overt retinopathy, attributable in part to subclinical choroidal dysfunction. In glaucoma, progression of visual field loss may correlate with decreasing choroidal blood flow, especially in normal-tension variants. These features underscore the importance of vigilant clinical observation and imaging in at-risk patients.
Advancements in ocular imaging have revolutionized the assessment of choroidal circulation. EDI-OCT provides high-resolution cross-sectional images, allowing precise measurement of choroidal thickness and evaluation of choroidal structure in vivo. OCTA enables non-invasive visualization of choroidal vasculature and quantification of flow deficits. Indocyanine green angiography remains valuable for assessing choroidal vascular permeability and is particularly useful in CSC and polypoidal choroidal vasculopathy. Emerging techniques, such as laser speckle flowgraphy and Doppler OCT, offer additional insights into choroidal hemodynamics. Integration of these modalities facilitates early detection of pathological changes, risk stratification, and monitoring of therapeutic response.
Management of diseases associated with choroidal circulation changes is multifaceted. In AMD, therapeutic strategies include intravitreal anti-VEGF agents, which target pathological neovascularization and may stabilize choroidal perfusion. Lifestyle modifications, such as smoking cessation and dietary interventions, are recommended to mitigate risk. CSC management ranges from observation for self-limiting cases to photodynamic therapy or mineralocorticoid receptor antagonists in chronic or recurrent disease, targeting choroidal hyperpermeability. Diabetic retinopathy treatment focuses on strict glycemic, blood pressure, and lipid control, with adjunctive intravitreal therapies in advanced stages. Glaucoma management centers on intraocular pressure reduction, but emerging evidence suggests that improving ocular blood flow may have adjunctive benefits. Individualized care, guided by imaging and risk assessment, is paramount.
Recent years have witnessed significant progress in understanding and managing choroidal circulation changes. Novel imaging biomarkers, such as the choroidal vascularity index and choriocapillaris flow voids, show promise for early disease detection and monitoring. Pharmacological agents targeting choroidal vascular tone and permeability, including endothelin receptor antagonists and selective mineralocorticoid receptor blockers, are under investigation. Gene therapy and regenerative approaches targeting choroidal ischemia hold potential for future intervention. Artificial intelligence algorithms are being developed to predict disease progression based on choroidal imaging metrics, facilitating personalized medicine. These advances are poised to enhance diagnostic precision and therapeutic outcomes.
Current clinical guidelines emphasize the importance of comprehensive ocular imaging in patients at risk for choroidal circulation abnormalities. The American Academy of Ophthalmology and the European Society of Retina Specialists recommend routine use of OCT and OCTA in monitoring patients with AMD, CSC, and diabetic retinopathy. Risk factor modification, including control of systemic hypertension and diabetes, is universally endorsed. In CSC, guidelines advocate for individualized management based on choroidal imaging findings and disease chronicity. Integration of choroidal assessment into routine clinical practice is increasingly recognized as a standard of care, reflecting its predictive and prognostic value.
Choroidal circulation changes represent a critical, yet often underappreciated, determinant of ocular disease onset and progression. Advances in imaging have transformed our ability to detect and quantify these changes, providing valuable predictive and prognostic information. Clinicians must remain vigilant in assessing choroidal health, particularly in high-risk populations, and integrate emerging evidence into individualized patient care. Ongoing research into the mechanisms, biomarkers, and therapeutic targets of choroidal dysfunction will continue to shape the future of ocular disease management and prevention.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation